Stability in community-acquired pneumonia: one step forward with markers?

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Biomarkers

Background:

• Systemic inflammation markers are crucial for assessing host response in community-acquired pneumonia (CAP).
• Evaluating procalcitonin (PCT) and C-reactive protein (CRP) for predicting stability and complications in CAP is essential.

Purpose of the Study:

• To assess if PCT and CRP levels at 72 hours reflect clinical stability in CAP patients.
• To determine if these markers can predict the absence of severe complications after initial treatment.

Main Methods:

• A prospective cohort study of 394 hospitalized CAP patients.
• Clinical stability assessed using modified Halm's criteria; PCT and CRP measured at baseline and 72 hours.
• Severe complications defined as mechanical ventilation, shock, ICU admission, or death post-72 hours.

Main Results:

• Patients achieving clinical stability at 72 hours had significantly lower CRP and PCT levels.
• Adding CRP to clinical stability criteria improved prediction of severe complications (AUC 0.84).
• Achieving clinical stability with low PCT (<0.25 ng/ml) and CRP (<3 mg/dl) at 72 hours precluded severe complications.

Conclusions:

• Low CRP and PCT levels at 72 hours, combined with clinical assessment, enhance prediction of no severe complications in CAP.
• These biomarkers offer valuable prognostic information beyond clinical evaluation.